) The Breast Oncology Program comprises 58 faculty members and Breast Cancer Advocates. Four major program grants and numerous individual investigator-initiated grants support the Program. These grants cover work in epidemiology, imaging, genetics, biology, therapeutics, and multidisciplinary clinical cancer management. The Breast Oncology Program is modeled after the Bay Area Breast Cancer SPORE, that is, it comprises collaborating clinical, population, laboratory researchers, and Breast Cancer Advocates working together to effectively translate laboratory and population research in breast into improved cancer management and control. Breast Oncology research is aimed at developing advanced imaging procedures to define tumor extent and quantify response to therapy; identifying genomic, epidemiological, or biological markers that define and/or predict disease progression or response to therapy; developing new therapies directed against specific genetic or biologic targets; and elucidating mechanisms through which tumors arise, progress, or respond to therapy. In addition, substantial effort is devoted to developing a clinical environment that guides, supports, and facilitates translation of laboratory and population into improved clinical care. Outcome assessment and modeling of breast cancer management are important components of this process. Research in these and other areas is stimulated through Program-sponsored developmental grants. Discussion forums include weekly SPORE and Program Project seminars; an annual Breast Oncology Program retreat; an informal afternoon discussion group; weekly Breast Tumor Board conferences; DOD-sponsored quarterly meetings of clinical investigators; monthly community forums; and patient-physician management discussion series.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA082103-01
Application #
6211769
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2002-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21

Showing the most recent 10 out of 192 publications